Incyte Corp (INCY): who owns it and who trades it
As of Nov 16, 2026, INCY insiders reported 49 open-market sales worth $66.1M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Steven H Stein (Vice president), with $35.8M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Incyte
From the latest filingsOverall: about as much buying as selling. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns INCY
856 funds and institutions reported INCY shares worth $23.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 15.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 30.76M | 15.40% | $3.5B | +0% |
| BlackRock, Inc. | 18.03M | 9.03% | $2B | -5% |
| Dodge & Cox | 11.96M | 5.99% | $1.4B | -2% |
| Vanguard Capital Management LLC | 11.02M | 5.52% | $1.2B | +1% |
| State Street Corp | 9.72M | 4.87% | $1.1B | +1% |
| Vanguard Portfolio Management LLC | 7.79M | 3.90% | $883M | +0% |
| AQR Capital Management LLC | 5.32M | 2.66% | $603M | -8% |
| Geode Capital Management, LLC | 4.75M | 2.38% | $537M | +1% |
| Lsv Asset Management | 4.12M | 2.06% | $467M | +5% |
| Invesco Ltd. | 4.08M | 2.04% | $463M | +5% |
| Wellington Management Group LLP | 3.58M | 1.79% | $405M | +9% |
| Renaissance Technologies LLC | 3.51M | 1.76% | $398M | -4% |
| Morgan Stanley | 2.95M | 1.48% | $334M | +3% |
| Arrowstreet Capital, Limited Partnership | 2.74M | 1.37% | $311M | -3% |
| Robeco Institutional Asset Management B.V. | 2.44M | 1.22% | $277M | -3% |
| Goldman Sachs Group Inc | 2.31M | 1.15% | $261M | -2% |
| Dimensional Fund Advisors LP | 2.28M | 1.14% | $259M | +15% |
| Two Sigma Investments, LP | 2.00M | 1.00% | $227M | +382% |
| Northern Trust Corp | 1.76M | 0.88% | $200M | -5% |
| Charles Schwab Investment Management Inc | 1.69M | 0.85% | $192M | -2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, INCY insiders reported $0 of open-market purchases and $66.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 35,042 | $116.06 | $4.1M | Form 4 |
| Nov 6, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 22,336 | $117.14 | $2.6M | Form 4 |
| Nov 6, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 60,270 | $118.27 | $7.1M | Form 4 |
| Nov 6, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 73,969 | $119.12 | $8.8M | Form 4 |
| Nov 6, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 48,576 | $119.66 | $5.8M | Form 4 |
| Nov 3, 2026 | Thomas Tray | Principal Accounting Off | Sale plan | 610 | $118.96 | $72.6K | Form 4 |
| Oct 15, 2026 | Pablo J Cagnoni | President | Sale plan | 2,642 | $112.71 | $298K | Form 4 |
| Sep 15, 2026 | Pablo J Cagnoni | President | Sale plan | 9,233 | $120.50 | $1.1M | Form 4 |
| Sep 15, 2026 | Pablo J Cagnoni | President | Sale plan | 13,985 | $120.49 | $1.7M | Form 4 |
| Aug 19, 2026 | Pablo J Cagnoni | President | Sale plan | 10,801 | $125.56 | $1.4M | Form 4 |
| Aug 12, 2026 | Pablo J Cagnoni | President | Sale plan | 10,803 | $120.04 | $1.3M | Form 4 |
| Aug 5, 2026 | Pablo J Cagnoni | President | Sale plan | 10,640 | $122.69 | $1.3M | Form 4 |
| Aug 5, 2026 | Patrick A Mayes | Vice president | Sale plan | 2,207 | $123.99 | $274K | Form 4 |
| Aug 3, 2026 | Patrick A Mayes | Vice president | Sale plan | 6,055 | $120.43 | $729K | Form 4 |
| Jul 31, 2026 | Pablo J Cagnoni | President | Sale plan | 15,888 | $119.70 | $1.9M | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 4,695 | $119.39 | $561K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 14,661 | $119.46 | $1.8M | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 5,332 | $119.42 | $637K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 2,187 | $119.47 | $261K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 6,171 | $119.43 | $737K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 2,864 | $119.40 | $342K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 1,643 | $119.51 | $196K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 1,642 | $119.38 | $196K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 85 | $122.19 | $10.4K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 326 | $121.69 | $39.7K | Form 4 |
| Jul 31, 2026 | Patrick A Mayes | Vice president | Sale plan | 2,293 | $119.41 | $274K | Form 4 |
| Jul 16, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 1,877 | $114.73 | $215K | Form 4 |
| Jul 16, 2026 | Mohamed Khairie Issa | Vice president | Sale plan | 1,093 | $115.01 | $126K | Form 4 |
| Jul 15, 2026 | Steven H Stein | CMO & Head of Late-Stage | Sale plan | 28,237 | $113.05 | $3.2M | Form 4 |
| Jun 4, 2026 | Thomas Tray | Principal Accounting Off | Sale plan | 2,639 | $100.00 | $264K | Form 4 |
| May 26, 2026 | Thomas Tray | Principal Accounting Off | Sale plan | 2,051 | $97.35 | $200K | Form 4 |
| May 19, 2026 | Paul J Clancy | Director | Sale plan | 15,000 | $94.93 | $1.4M | Form 4 |
| Apr 17, 2026 | Pablo J Cagnoni | President | Sale plan | 18,667 | $96.50 | $1.8M | Form 4 |
| Mar 17, 2026 | Pablo J Cagnoni | President | Sale plan | 18,667 | $94.24 | $1.8M | Form 4 |
| Feb 19, 2026 | Pablo J Cagnoni | President | Sale plan | 18,668 | $100.91 | $1.9M | Form 4 |
| Jan 7, 2026 | Mohamed Khairie Issa | Vice president | Sale plan | 10,856 | $109.07 | $1.2M | Form 4 |
| Jan 5, 2026 | Steven H Stein | Vice president | Sale plan | 15,634 | $101.70 | $1.6M | Form 4 |
| Dec 19, 2025 | Thomas Tray | Principal Accounting Off | Sale plan | 2,774 | $100.00 | $277K | Form 4 |
| Dec 18, 2025 | Thomas Tray | Principal Accounting Off | Sale plan | 600 | $98.25 | $59K | Form 4 |
| Dec 17, 2025 | Michael James Morrissey | Vice president | Sale plan | 4,323 | $97.26 | $420K | Form 4 |
| Dec 16, 2025 | Michael James Morrissey | Vice president | Sale plan | 833 | $97.42 | $81.2K | Form 4 |
| Dec 16, 2025 | Michael James Morrissey | Vice president | Sale plan | 53,175 | $97.29 | $5.2M | Form 4 |
| Dec 11, 2025 | Patrick A Mayes | Vice president | Sale plan | 255 | $94.94 | $24.2K | Form 4 |
| Dec 10, 2025 | Patrick A Mayes | Vice president | Sale plan | 5,553 | $95.58 | $531K | Form 4 |
| Dec 2, 2025 | Steven H Stein | Vice president | Sale plan | 20,105 | $102.51 | $2.1M | Form 4 |
| Dec 1, 2025 | Steven H Stein | Vice president | Sale plan | 2,559 | $102.96 | $263K | Form 4 |
| Nov 24, 2025 | Thomas Tray | Principal Accounting Off | Sale plan | 600 | $103.00 | $61.8K | Form 4 |
| Nov 21, 2025 | Thomas Tray | Principal Accounting Off | Sale plan | 169 | $102.00 | $17.2K | Form 4 |
| Nov 17, 2025 | Sheila A. Denton | Vice president | Sale plan | 278 | $104.36 | $29K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Steven H Stein | EVP & Chief Medical Officer | – | $35.8M | Nov 6, 2026 |
| Pablo J Cagnoni | President, R&D | – | $14.4M | Oct 15, 2026 |
| Patrick A Mayes | EVP & Chief Scientific Officer | – | $6.6M | Aug 5, 2026 |
| Michael James Morrissey | EVP, Head of Tech. Operations | – | $5.7M | Dec 17, 2025 |
| Paul J Clancy | Director | – | $1.4M | May 19, 2026 |
| Mohamed Khairie Issa | EVP, Head of US Oncology | – | $1.3M | Jul 16, 2026 |
| Thomas Tray | Principal Accounting Officer | – | $952K | Nov 3, 2026 |
| Sheila A. Denton | EVP & General Counsel | – | $29K | Nov 17, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INCY short interest
Moderate short interest. 5.2% of INCY shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.65M INCY shares were sold short, 5.2% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.65M | 5.22% | +6% | 1.91M | 5.6 |
| Oct 15, 2026 | 10.03M | 4.95% | +0% | 1.89M | 5.3 |
| Sep 30, 2026 | 9.99M | 4.93% | +0% | 1.65M | 6.1 |
| Sep 15, 2026 | 9.98M | 4.92% | +7% | 1.38M | 7.3 |
| Aug 31, 2026 | 9.36M | 4.62% | -0% | 1.22M | 7.7 |
| Aug 14, 2026 | 9.39M | 4.63% | -8% | 1.41M | 6.7 |
| Jul 31, 2026 | 10.25M | 5.06% | -3% | 2.13M | 4.8 |
| Jul 15, 2026 | 10.51M | 5.26% | -1% | 1.63M | 6.5 |
| Jun 30, 2026 | 10.58M | 5.30% | +0% | 2.20M | 4.8 |
| Jun 15, 2026 | 10.56M | 5.29% | -7% | 2.23M | 4.7 |
| May 29, 2026 | 11.40M | 5.71% | +3% | 1.24M | 9.2 |
| May 15, 2026 | 11.04M | 5.53% | -3% | 1.28M | 8.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded INCY
Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of INCY. The latest was a sale by Robert P. Bresnahan, Jr. on May 15, 2025, reported May 31, 2025.
Purchases 0Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | May 31, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Incyte company events
Incyte filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Aug 31, 2026AnnouncementIncyte Corporation today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation. Filing
- Jul 28, 2026ResultsReleased financial results. Filing
- Jul 6, 2026AnnouncementIncyte Corporation issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. Filing
- Jun 22, 2026AnnouncementIncyte Corporation today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura ® (ruxolitinib) cream. Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- Jun 8, 2026AnnouncementIncyte Corporation issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC. Filing
- Apr 28, 2026ResultsReleased financial results. Filing
- Mar 30, 2026LeadershipSusanne Schaffert notified Incyte Corporation that she was resigning from the Company’s Board of Directors, effective as of April 15, 2026. Filing
- Mar 26, 2026LeadershipIncyte Corporation announced title changes for certain current members of its executive leadership team, effective immediately. Filing
- Mar 6, 2026AnnouncementThe U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer in combination with… Filing
- Feb 10, 2026ResultsReleased financial results. Filing
- Dec 12, 2025LeadershipHervé Hoppenot notified Incyte Corporation that he was retiring from the Company’s Board of Directors, effective immediately. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Incyte financials
Famous investors that hold INCY
8 of the 50 well-known investors we track reported holding INCY in their latest 13F filing. The largest position is Jim Simons's, worth $404M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 3.33M | $404M | 0.5% | -5% |
| Jeremy Grantham · GMO | Q3 2026 | 293,623 | $35.6M | 0.1% | -8% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 203,799 | $24.7M | 0.1% | +21% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 145,442 | $17.6M | 0.0% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 62,777 | $7.6M | 0.0% | -56% |
| Israel Englander · Millennium Management | Q3 2026 | 40,188 | $4.9M | 0.0% | -51% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 5,000 | $607K | 0.0% | New |
| Lee Ainslie · Maverick Capital | Q3 2026 | 2,489 | $302K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named INCY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Dodge & Cox | 13G/A | 5.0% |
| Nov 12, 2026 | Dodge & Cox | 13G/A | 5.0% |
Questions about Incyte Corp (INCY) stock
Who owns the most INCY stock?
The largest reported owner of Incyte Corp (INCY) is Baker Bros. Advisors LP, with 15.4% of the company. In total, 856 funds and institutions reported holding INCY at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are INCY insiders buying or selling?
In the last 12 months, INCY insiders reported no open-market purchases and 49 sales worth $66.1M. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in INCY?
As of Oct 30, 2026, 10.65M INCY shares were sold short, 5.2% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.6 trading days (days to cover). See the history.
Have members of Congress traded INCY?
Yes. 1 member of Congress reported 0 purchases and 1 sale of INCY since Nov 17, 2024. The latest was reported on May 31, 2025. See the trades.
Which famous investors hold INCY?
8 of the 50 well-known investors we track reported INCY in their latest 13F filing, including Jim Simons, Jeremy Grantham, Ray Dalio. The largest position is worth $404M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.